Pharmacogenetics of Anticoagulants

Pharmacogenetics of oral anticoagulant therapy

Use of genetic data to guide therapy in arterial disease.

There is considerable interindividual variation in the response to antiplatelet and anticoagulant therapies. It has been proposed that this variability in drug response may be attributable to genetic variants. Thus, pharmacogenetics may help to accurately predict response to cardiovascular disease (CVD) therapies in order to maximize drug efficacy, minimize drug toxicity, and to tailor personal...

Genotype-guided dosing of vitamin K antagonists.

To the Editor: Three articles in the December 12 issue1-3 address pharmacogenetics and dosing of coumarin anticoagulants. Because it is more usual for elderly patients to have an international normalized ratio (INR) outside the targeted therapeutic range and to have frank bleeding, it would be of clinical interest to know whether the authors stratified patients by age and whether coexisting con...

Warfarin Pharmacogenetics: New Life for an Old Drug.

UNLABELLED Warfarin was first introduced in the 1950s and quickly became the most commonly used oral anticoagulant for the prevention of thromboembolism in patients with deep vein thrombosis, atrial fibrillation, or prosthetic heart valve replacement. Warfarin is highly effective in treating these diseases; however, several factors prevent it from even wider use, especially in Asian populations...

Impact of genetic polymorphisms on clinical response to antithrombotics

Antithrombotic therapy, including anticoagulants as well as antiplatelet drugs, is an important component in the treatment of cardiovascular disease. Variability in response to such medications, of which pharmacogenetic response is a major source, can decrease or enhance the benefits expected. This review is a comprehensive assessment of the literature published to date on the effects of geneti...